Deals channel feed

No deal for Mer­ck and Seagen yet as talks stall over buy­out price — re­port

3 years ago

Af­ter wrestling with the San­doz prob­lem for sev­er­al years, Vas Narasimhan set­tles on a spin­out

3 years ago

Al­con, No­var­tis' for­mer eye dis­ease unit, con­tin­ues deal­mak­ing spree with $770M Aerie ac­qui­si­tion

3 years ago
R&D

Four of­fers and a call from Bourla: How Pfiz­er nar­row­ly beat out ri­val bid­der to swal­low GBT and its sick­le cell drugs for $5.4B

3 years ago

Roche, Genen­tech plunk down $60M up­front to part­ner with Chi­nese phar­ma on PRO­TAC-based prostate can­cer drug

3 years ago
China

Ex­sci­en­tia ter­mi­nates Bay­er pact half a year ear­ly, col­lect­ing small por­tion of €240M promised

3 years ago
AI

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

3 years ago

A cou­ple bil­lion for Ex­sci­en­tia was on­ly part of Sanofi's AI am­bi­tions, as the Big Phar­ma adds Atom­wise to the ta­ble

3 years ago
AI

Bris­tol My­ers gets nec­es­sary clear­ance for $4.1B Turn­ing Point ac­qui­si­tion

3 years ago
R&D
Pharma

Gos­sip in Baby­lon: Dig­i­tal health com­pa­ny paints M&A ru­mors as flat-out wrong

3 years ago
Financing

Gilead doles out $280M up­front to re­gain Trodelvy rights in Chi­na, oth­er re­gion­al ter­ri­to­ries

3 years ago

'We have failed to fail': Mer­ck gam­bles $250M cash on a next-gen ap­proach to mR­NA — af­ter punt­ing its big al­liance with Mod­er­na

3 years ago

Re­silience col­lab­o­rates with the Mayo Clin­ic to man­u­fac­ture rare and com­plex dis­ease drugs

3 years ago
Cell/Gene Tx
Manufacturing

Ideaya stock slashed af­ter GSK punts an op­tion

3 years ago
R&D

Ad­vent to sell stake in man­u­fac­tur­er and drug de­vel­op­er in a deal worth over $1B — re­port

3 years ago
Manufacturing

Catal­ent ac­quires North Car­oli­na CD­MO for $475M, boost­ing oral solids work

3 years ago
Manufacturing

In bid for new T cell ther­a­pies, Bris­tol My­ers inks deal with Treg play­er Gen­tiBio

3 years ago

Disc Med­i­cine goes pub­lic in re­verse merg­er with strug­gling Gem­i­ni Ther­a­peu­tics

3 years ago

On an ex­pan­sion spree, Ger­man man­u­fac­tur­er Sar­to­rius makes $500M+ pur­chase of cell cul­ture me­dia play­er

3 years ago
Outsourcing
Cell/Gene Tx

Mer­ck makes first big splash for Alzheimer’s drug R&D since 2017 fail, ink­ing re­search pact with Cere­vance

3 years ago

In $1.36B biobuck deal with GSK, Mer­sana touts 'biggest pre­clin­i­cal ADC deal ever'

3 years ago
Pharma

Sarep­ta li­cens­es next-gen AAV tech from Broad In­sti­tute in deal cov­er­ing five in­di­ca­tions — in­clud­ing Duchenne

3 years ago

Up­dat­ed: Pfiz­er scoops up Glob­al Blood Ther­a­peu­tics and its sick­le cell ther­a­pies for $5.4B

3 years ago

Break­ing: Pfiz­er in hot pur­suit of a $5B buy­out of Glob­al Blood Ther­a­peu­tics — re­port

3 years ago
First page Previous page 53545556575859 Next page Last page
A service from the Financial Times